The exact process of chronic lymphocytic leukemia patients developing resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug, has been understood by a multi-institutional team of researchers. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of new agents to treat drug-resistant disease. Ibrutinib received accelerated ...Thursday, 29 May 2014
Drug Resistance Due to Tiny Mutation in Certain Leukemia Patients
The exact process of chronic lymphocytic leukemia patients developing resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug, has been understood by a multi-institutional team of researchers. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of new agents to treat drug-resistant disease. Ibrutinib received accelerated ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment